Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes

被引：3

作者：

Garcia, Jacqueline S. ^{[1
]}

Platzbecker, Uwe ^{[2
]}

Odenike, Olatoyosi ^{[3
]}

Fleming, Shaun ^{[4
]}

Fong, Chun Yew ^{[5
]}

Cook, Rachel ^{[6
]}

Jacoby, Meagan ^{[7
]}

Nowak, Daniel ^{[8
]}

Chyla, Brenda ^{[9
]}

Zhou, Ying ^{[9
]}

Ku, Grace ^{[10
]}

Potluri, Jalaja ^{[9
]}

Garcia-Manero, Guillermo ^{[11
]}

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[2] Univ Med Ctr Leipzig, Dept Hematol Cellular Therapy Hemostaseol & Infec, Leipzig, Germany

[3] Univ Chicago Med, Chicago, IL USA

[4] Alfred Hlth, Melbourne, Australia

[5] Austin Hlth, Dept Hematol, Heidelberg, Australia

[6] Oregon Hlth & Sci Univ, Portland, OR USA

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] Heidelberg Univ, Med Fac Mannheim, Mannheim, Germany

[9] AbbVie Inc, N Chicago, IL USA

[10] Genentech Inc, San Francisco, CA USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-189446

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results
Wei, Andrew H.
Garcia, Jacqueline S.
Borate, Uma
Fong, Chun Yew
Baer, Maria R.
Nowak, Daniel
Peterlin, Pierre
Jurcic, Joseph
Jacoby, Meagan A.
Platzbecker, Uwe
Odenike, Olatoyosi
Cunningham, Ilona
Zhou, Ying
Hoffman, David
Hogdal, Leah
Naqvi, Kiran
Kye, Steve
Garcia-Manero, Guillermo
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S343 - S343
[2] Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
Al Ali, Najla
Sallman, David
Chan, Onyee
Padron, Eric
Sweet, Kendra
Kuykendall, Andrew
Lancet, Jeffrey
Komrokji, Rami
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S341 - S341
[3] Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naive higher-risk myelodysplastic syndromes.
Fong, Chun Yew
Wei, Andrew H.
Frattini, Mark G.
Jacoby, Meagan
Borate, Uma
Gotze, Katharina S.
Garcia, Jacqueline Suen
Pollyea, Daniel Aaron
Holes, Leanne
Zhou, Ying
Fakouhi, Kaffa Mussumeh
Leverson, Joel
Harb, Jason G.
Agarwal, Suresh K.
Attarchi, Faraneh
Mabry, Mack H.
Hong, Wan-Jen
Jahn, Thomas Michael
Fenaux, Pierre
Garcia-Manero, Guillermo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome
Wei, Andrew H.
Garcia, Jacqueline S.
Borate, Uma
Fong, Chun Yew
Baer, Maria R.
Nolte, Florian
Peterlin, Pierre
Jurcic, Joseph G.
Garcia-Manero, Guillermo
Hong, Wan-Jen
Platzbecker, Uwe
Odenike, Olatoyosi
Dunbar, Martin
Zhou, Ying
Harb, Jason
Tanwani, Poonam
Wolff, Johannes E.
Jacoby, Meagan
[J]. BLOOD, 2019, 134
[5] Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes
Rajakumaraswamy, Nishanthan
Gandhi, Mitul
Wei, Andrew H.
Sallman, David A.
Daver, Naval G.
Mo, Shuyuan
Iqbal, Shahed
Karalliyadda, Roshan
Chen, Manli
Wang, Yunfei
Vyas, Paresh
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04):
[6] Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation
Garcia-Manero, Guillermo
Odenike, Olatoyosi
Fleming, Shaun
Roboz, Gail J.
Jacoby, Meagan
Cunningham, Ilona
Kreuzer, Karl-Anton
Enjeti, Anoop K.
Baer, Maria R.
Cook, Rachel
Jurcic, Joseph
Ku, Grace
Zhou, Ying
Hoffman, David
Potluri, Jalaja
Garcia, Jacqueline S.
[J]. BLOOD, 2023, 142
[7] Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naive Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine
Garcia, Jacqueline S.
Wei, Andrew H.
Jacoby, Meagan A.
Fong, Chun Yew
Borate, Uma
Baer, Maria R.
Cunningham, Ilona
Odenike, Olatoyosi
Jurcic, Joseph G.
Nowak, Daniel
Peterlin, Pierre
Platzbecker, Uwe
Dunshee, Diana
Zhou, Ying
Hoffman, David
Sun, Yan
Popovic, Relja
Ainsworth, Barrett
Naqvi, Kiran
Kye, Steve
Hogdal, Leah
Garcia-Manero, Guillermo
[J]. BLOOD, 2021, 138
[8] Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naive higher-risk myelodysplastic syndromes.
Zeidan, Amer Methqal
Garcia, Jacqueline Suen
Fenaux, Pierre
Platzbecker, Uwe
Miyazaki, Yasushi
Xiao, Zhi-Jian
Zhou, Ying
Naqvi, Kiran
Kye, Steve
Garcia-Manero, Guillermo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[9] Phase 2 Expansion Study of Oral Rigosertib Combined With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Efficacy and Safety Results in HMA Treatment-Naive and Relapsed/Refractory Patients
不详
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 8 - 9
[10] Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
Chou, Wen-Chien
Yeh, Su-Peng
Hsiao, Liang-Tsai
Lin, Sheng-Fung
Chen, Yeu-Chin
Chen, Tsai-Yun
Laille, Eric
Galettis, Anoula
Dong, Qian
Songer, Steve
Beach, C. L.
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E430 - E439

← 1 2 3 4 5 →